HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooper, W. O. Articles by Griffin, M. R. Search for Related Content PubMed PubMed Citation Articles by Cooper, W. O. Articles by Griffin, M. R.

Prenatal Prescription of Macrolide Antibiotics and Infantile Hypertrophic Pyloric Stenosis

From the Division of General Pediatrics, Department of Pediatrics, and Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University, Nashville, Tennessee.

Address reprint requests to: William O. Cooper, MD, MPH, Vanderbilt University School of Medicine, Division of General Pediatrics, Suite 5028 MCE, Nashville, TN 37232-8555; E-mail: william.cooper{at}mcmail.vanderbilt.edu.

OBJECTIVE: To assess the association between prenatal antibiotics, including erythromycin, and infantile hypertrophic pyloric stenosis in a large cohort of infants.

METHODS: This was a retrospective cohort study of births to women enrolled in Tennessee Medicaid/TennCare, 1985–1997. Prescriptions for erythromycin, nonerythromycin macrolides, and other antibiotics were identified from pharmacy files linked with birth certificate files. The primary study outcome was development of pyloric stenosis in the infant, identified from linked hospital discharge diagnosis and surgical procedure codes.

RESULTS: The cohort included 260,799 mother/infant pairs. Among these women, 13,146 filled prescriptions for erythromycin (50.4 per 1000), and 621 filled prescriptions for nonerythromycin macrolides (2.4 per 1000). There was no association with prenatal erythromycin prescription and infantile hypertrophic pyloric stenosis either after 32 weeks’ gestation (adjusted odds ratio 1.17, 95% confidence interval, 0.84, 1.64, P = .33) or at any time during pregnancy (adjusted odds ratio 1.15, 95% confidence interval 0.84, 1.56, P = .36). There was an association between maternal prescriptions for nonerythromycin macrolides and infantile hypertrophic pyloric stenosis (adjusted odds ratio 2.77, 95% confidence interval 1.22, 6.30, P = .01).

CONCLUSION: The hypothesized association between erythromycin and infantile pyloric stenosis was not seen. Causal inference from the association between prenatal nonerythromycin macrolides and infantile hypertrophic pyloric stenosis is limited by the small number of affected children and the evidence of other differences between users of nonerythromycin macrolides and controls.

This article has been cited by other articles:

				W. O. Cooper, S. Hernandez-Diaz, P. G. Arbogast, J. A. Dudley, S. Dyer, P. S. Gideon, K. Hall, and W. A. Ray Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med., June 8, 2006; 354(23): 2443 - 2451. [Abstract] [Full Text] [PDF]

				C. M. Sox, W. O. Cooper, T. D. Koepsell, D. L. DiGiuseppe, and D. A. Christakis Provision of Pneumococcal Prophylaxis for Publicly Insured Children With Sickle Cell Disease JAMA, August 27, 2003; 290(8): 1057 - 1061. [Abstract] [Full Text] [PDF]

				J. Roig and J. Rello Legionnaires' disease: a rational approach to therapy J. Antimicrob. Chemother., May 1, 2003; 51(5): 1119 - 1129. [Abstract] [Full Text] [PDF]

				C. Louik, A. A. Mitchell, W. O. Cooper, W. A. Ray, and M. R. Griffin Prenatal Prescription of Macrolide Antibiotics and Infantile Hypertrophic Pyloric Stenosis Obstet. Gynecol., April 1, 2003; 101(4): 816 - 817. [Full Text] [PDF]